Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) EPS (Basic) (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed EPS (Basic) for 6 consecutive years, with $0.07 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 333.33% year-over-year to $0.07, compared with a TTM value of $0.0 through Dec 2025, up 100.91%, and an annual FY2025 reading of $0.0, up 100.93% over the prior year.
  • EPS (Basic) was $0.07 for Q4 2025 at Xeris Biopharma Holdings, up from $0.0 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.07 in Q4 2025 and bottomed at -$0.45 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$0.15, with a median of -$0.12 recorded in 2024.
  • The sharpest move saw EPS (Basic) dropped 22.22% in 2024, then skyrocketed 333.33% in 2025.
  • Year by year, EPS (Basic) stood at -$0.45 in 2021, then soared by 77.78% to -$0.1 in 2022, then grew by 10.0% to -$0.09 in 2023, then soared by 66.67% to -$0.03 in 2024, then surged by 333.33% to $0.07 in 2025.
  • Business Quant data shows EPS (Basic) for XERS at $0.07 in Q4 2025, $0.0 in Q3 2025, and -$0.01 in Q2 2025.